

OBIL/BSE/20/2019-2020

12th August, 2019

To,
The Corporate Relations Department
The Bombay Stock Exchange Ltd,
P J Towers, 1st Floor,
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Ref: Scrip Code: **538019**

ISIN: **INE732P01018**

Sub: Submission of Standalone Unaudited Financial Results for the quarter ended 30th June, 2019.

This is to inform you that the meeting of the Board of Directors was held today, 12th August, 2019 inter alia, to consider and approve the Unaudited (limited reviewed) Financial Results for the quarter ended 30.06.2019.

In this regard, the following documents are enclosed herewith:


- Standalone Unaudited Financial Results for the quarter ended 30.06.2019 - Regulation 33 - Annexure I of SEBI (LODR) Regulations, 2015.
- Limited review report signed by the Statutory Auditor

The meeting commenced at 04:00 p.m. and concluded at 06:00 p.m.

Kindly update the above in your records.


Thanking You.

For Oceanaa Biotek Industries Limited



Xavier Jeyaraj
Managing Director

Encl: As above



M/S. OCEANAA BIOTEK INDUSTRIES LIMITED

CIN: L15549TN2005PLC057919

No.4B-1, Eastern Portion, 4th Floor, Centre Point Apartment, Sadhullah Street, T Nagar, Chennai - 600017

Unaudited Standalone Financial Results for the Quarter Ended 30th June 2019


in lakhs except earnings per share and share information/data

S.No.	Particulars	Quarter Ended			Year Ended
		30-06-2019	31-03-2019	30-06-2018	31-03-2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from Operations				
	a) Sale of products	454.91	324.00	1,101.91	3,628.19
	b) Other Operating Revenues	-	-	-	-
	Total Revenue from Operations	454.91	324.00	1,101.91	3,628.19
2	Other Income	0.22	0.11	0.10	0.62
3	Total Income (1+2)	455.14	324.11	1,102.01	3,628.81
4	Expenses				
	a) Cost of Materials Consumed	162.25	785.00	583.70	2,645.57
	b) Purchase of Stock-in-Trade	-	-	-	-
	"c) Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-Trade"	24.23	338.14	117.94	587.47
	d) Employee Benefits Expense	40.06	15.56	62.95	192.87
	e) Depreciation and Amortisation Expense	53.85	13.62	78.89	250.43
	f) Finance Costs	2.01	2.48	3.11	11.50
	g) Other Expenses	55.63	1,547.12	181.84	1,997.51
	Total Expenses	338.02	2,701.92	1,028.42	5,685.35
5	Profit Before Exceptional Items and Tax (3 - 4)	117.11	(2,377.81)	73.59	(2,056.53)
6	Exceptional Items [Refer Note 4]				
7	Profit Before Tax (5 + 6)	117.11	(2,377.81)	73.59	(2,056.53)
8	Tax Expense				
	Current Tax	-	-	21.22	-
	Current Tax - Earlier Years	-	-	-	-
	Deferred Tax Asset/ (Liability)	(1.31)	-	(55.35)	(51.22)
	Total	(1.31)	-	(34.13)	(51.22)
9	Profit After Tax (7 - 8)	118.42	(2,377.81)	107.72	(2,005.31)
10	Other Comprehensive Income				
	"a) Items not to be reclassified to profit or loss in subsequent periods"	-	7.47	-	7.47
	"Re-measurement Gains and (Losses) on Defined Benefit Obligations (Net) and Net (Loss)/Gain on FVTOCI Equity Securities"	-	-	-	-
	Income Tax Effect	-	-	-	-
	"b) Items to be reclassified to profit or loss in subsequent periods"	-	-	-	-
	Net movement on cash flow hedges	-	-	-	-
	Income Tax Effect	-	-	-	-
	Other Comprehensive Income for the period	-	7.47	-	7.47
11	Total Comprehensive income (9 + 10)	118.42	(2,370.34)	107.72	(1,997.84)
12	Paid-up Equity Share Capital (Face Value of 71 Each)	135,652,750	135,652,750	135,652,750	135,652,750
13	Reserves and Surplus (i.e Other Equity)	1,289.93	1,169.70	1,201.39	1,169.70
14	Networth	2,646.46	2,526.23	2,557.91	2,526.23
15	Basic Earnings Per Share - Not Annualised	0.87	(17.53)	0.79	(14.78)
16	Diluted Earnings Per Share - Not Annualised	0.87	(17.53)	0.79	(14.78)

Notes:

- The Audited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 12th Aug, 2019
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Sec 133 of the Companies Act 2013 and other recognised accounting practices and policies to the extent applicable.
- Figures of the previous period/year are reclassified /regrouped or rearranged wherever necessary to make it comparable.
- There are no separate reportable segments for the three months ended Jun 2019 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standard) Rules 2014.
- There were no Investors' Complaints received during the period.
- All the financial numbers presented above are prepared as per the IND

Signed on Behalf of Board of Directors



Thomas Xavier Jeyaraj
Managing Director
PIN: 06896574

Place: Chennai
Date: 12-Aug-2019

To
The Board of Directors,
No.4B-1 Eastern Portion, 4th Floor, Centre Point Apartment,
Sadhullah Street, T Nagar, Chennai 600 017,
Tamil Nadu


Dear Sir/Madam,

We hereby confirm the following in respect of the unaudited financial statements for the quarter ended on 30th June, 2019 being presented before the Board at the meeting to be held on 12th August, 2019.

- (1) That to the best of our knowledge, the financial results do not contain any false or misleading statement of figures.
- (2) That to the best of our knowledge, the financial results do not omit any material fact which may make the statements or figures contained therein misleading.

Yours sincerely

Place: Chennai
Date: 12.08.2019



Xavier Jeyaraj
Managing Director
DIN: 06896574

Limited Review Report for the Quarter Ending 30th June 2019

To
The Board of Directors
M/s. OCEANAA BIOTEK INDUSTRIES LIMITED
No.6, 1st Floor, Wellington Estate
53, Ethiraj Salai, Egmore
Chennai – 600 008, Tamil Nadu.

We have reviewed the accompanying statement of audited financial results (the "statement") of M/s. OCEANAA BIOTEK INDUSTRIES LIMITED ("the Company") for the period ended 30.06.2019 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No CIR/CFD/FAC/62/2016 dated July 5, 2016.


The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS) 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 read with SEBI circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have performed our audit and accordingly, we do express our opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of audited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ABHAY JAIN & CO.
Chartered Accountants
FRN: 0000008S

Date: 12/08/2019
Place: Chennai


(A.K. Jain)
M NO: 070224



Date: 12th August, 2019

DECLARATION

M/s Abhay Jain & Co., Chartered Accountants, Statutory Auditor of the Company have given an unmodified opinion with respect to the Standalone Audited Financial Results for the half yearly and year ended 30th June, 2019.


This declaration is submitted in compliance with Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulation, 2016, as issued by SEBI vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May, 25, 2016.

For Oceanaa Biotek Industries Limited

Xavier Jeyaraj
Managing Director
Place: Chennai



For Abhay Jain & Co
Chartered Accountants
FRN: 0000085


CA A K JAIN 12.08.2019

Partner

M No: 070224

